What Happened?
Cambridge, -based Bluebird-Bio Resigned Anne-Virginie Eggimann as Chief Regulatory Officer
About the Company
At Bluebird Bio, we`re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – to ensure lives are lived fully. To do it, we`re developing one-time gene therapies for severe genetic disease and cancer, while working to radically improve healthcare systems so gene therapy becomes truly accessible. We want to recode science, systems and the status quo – for life. We pride ourselves on having a unique culture that drives our success. A diverse flock of individual birds, we share common DNA that helps us build meaningful relationships with industry, patient & advocacy groups and our customers. We fly as one and invite others to join us. We`re headquartered in Cambridge, MA with additional nests in Seattle, WA, Durham, NC, and Zug, Switzerland.
About the Person
Anne-Virginie Eggimann is Chief Regulatory Officer at Tessera Therapeutics. Previously, Anne-Virginie held various senior legal leadership roles in the industry.
Info Source
News
Short Profile